T-regulatory cells are an upsurge in the tumor microenvironment and induce immune-evasion. CD4 + Treg cells are well characterized whereas the role of CD8 + Tregs in cancer has recently started to crease attention. Here, we report an augmentation CD8 + FOXP3 + Tregs in breast tumor microenvironment. FOXP3, the lineage-specific transcription factor, is a dominant regulator of Treg cell development and function. FOXP3 is induced preferentially by divergent signaling in CD4 + Treg cells. But how FOXP3 is induced and maintained in tumor-CD8 + Tregs is the Cinderella of the investigation. We observed that RUNX3, a CD8 + lineage-specific transcription factor, binds at the FOXP3 -promoter to induce its transcription. In addition to promoter activation, involvement of cis -elements CNS1 and CNS2 in the transcriptional regulation of FOXP3 was also evident in these cells. SMAD3 binds to CNS1 region and acts as transcription inducer, whereas GATA3 plays a temporal role in the FOXP3 transcription by differential chromatin modification in CNS regions. In CNS1 region, GATA3 acts as a repressor for FOXP3 in naïve CD8 + T cells. Whereas in CD8 + Tregs, GATA3 binds directly at CNS2 region and persuaded the maintenance of FOXP3 . Therefore, the intervention of these concerted transcriptional machinery may have a therapeutic potential in immunotherapy of cancer.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: